Thursday 16 October, 2025
Objectives: To stablish a semi-mechanistic model describing the time course of several circulating biomarkers (LDH, S-100B, and MIA) in advanced melanoma…
Read morePoster: Drug/Disease Modelling - Oncology
In vitro data supporting circulating CCCK18 as potential pharmacodynamic biomarker in ovarian cancer
Thursday 16 October, 2025
Objectives: Circulating full-length and caspase-cleaved (cc) cytokeratin (CK) 18 are used in the study of apoptosis and chemotherapy-induced cell death. In…
Read moreTarget-mediated drug disposition modeling of lacnotuzumab in healthy volunteers and patients with advanced malignancies and triple negative breast cancer.
Thursday 16 October, 2025
Objectives: Lacnotuzumab is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor (CSF-1) known as the primary…
Read morePopulation pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma.
Thursday 16 October, 2025
Objectives: Pazopanib, a tyrosine kinase inhibitor [1], has been approved as monotherapy for patients with advanced renal cell carcinoma and…
Read morePopulation pharmacokinetic/pharmacodynamic modeling to evaluate target suppression in patients with advanced solid tumors by ginisortamab, an anti-gremlin-1 monoclonal antibody
Thursday 16 October, 2025
Introduction: Ginisortamab, a fully human IgG4 monoclonal antibody with first-in-class potential, neutralizes gremlin-1 and showed antitumor activity in several mouse…
Read morePopulation pharmacokinetic analysis of erlotinib in cancer patients affected by NSCLC
Thursday 16 October, 2025
Objectives: Erlotinib is an oral first-generation EGFR tyrosine kinase inhibitor approved in patients with non-small cell lung cancers (NSCLC) with…
Read moreModeling of radiation therapy and radiosensitizing agents in tumor xenografts
Thursday 16 October, 2025
Objectives: To conceptually and mathematically describe the treatment effects of radiation and radiosensitizing agents on tumor volume in xenografts with respect…
Read moreTumor Static Exposure for anticancer combinations in early drug discovery
Thursday 16 October, 2025
Objectives: Examine how the Tumor Static Exposure (TSE) concept can help guide early drug discovery, particularly for combination treatments with…
Read moreArtificial neural networks can facilitate the analysis and prediction of longitudinal tumour size data: an example from a non-small cell lung cancer phase III study
Thursday 16 October, 2025
Objectives: Artificial Neural Networks (NN) are an important component of modern Machine Learning. They have been used in a wealth…
Read moreExposure response relationship for interstitial lung disease (ILD) events following osimertinib treatment
Thursday 16 October, 2025
Objectives: Osimertinib is indicated for the treatment of patients with T790M mutation positive advanced non-small cell lung cancer (NSCLC) who have…
Read more